[
    {
        "role": "user",
        "content": "Study effectiveness and safety of Farxiga (Dapagliflozin) in Type 2 Diabetes Mellitus Management for senior population."
    },
    {
        "role": "assistant",
        "content": "I need some clarification to better understand your research needs:",
        "questions": [
            "Are there specific cardiovascular, renal, or glycemic outcomes of particular interest when evaluating the effectiveness of Farxiga in elderly T2DM patients?",
            "Is the target audience for this research other researchers, clinicians, policymakers, or patients, and how will this influence the level of detail required?",
            "Beyond efficacy and adverse events, should the research also consider patient-reported outcomes, quality of life, or healthcare costs associated with Farxiga use in this population?",
            "Are there any specific subgroups within the senior population (e.g., based on age, comorbidities, frailty) that should be prioritized in the analysis?",
            "Are you interested in comparing Farxiga to specific alternative treatments or standard care approaches currently used in elderly T2DM patients?"
        ]
    },
    {
        "role": "user",
        "content": "I approve this research plan."
    },
    {
        "role": "assistant",
        "content": "Thank you! I'll start the research process now. You can see my progress on the right panel."
    }
]

----------------

{
    "detail": [
        {
            "type": "missing",
            "loc": [
                "body",
                "chat_history"
            ],
            "msg": "Field required",
            "input": {
                "research_id": "b70727e4-c03f-4ae8-8227-81bf56e5c0d3",
                "version": "khkqwhek9873912739",
                "messages": [
                    {
                        "role": "user",
                        "content": "Study effectiveness and safety of Farxiga (Dapagliflozin) in Type 2 Diabetes Mellitus Management for senior population."
                    },
                    {
                        "role": "assistant",
                        "content": "I need some clarification to better understand your research needs:",
                        "questions": [
                            "Are there specific cardiovascular, renal, or glycemic outcomes of particular interest when evaluating the effectiveness of Farxiga in elderly T2DM patients?",
                            "Is the target audience for this research other researchers, clinicians, policymakers, or patients, and how will this influence the level of detail required?",
                            "Beyond efficacy and adverse events, should the research also consider patient-reported outcomes, quality of life, or healthcare costs associated with Farxiga use in this population?",
                            "Are there any specific subgroups within the senior population (e.g., based on age, comorbidities, frailty) that should be prioritized in the analysis?",
                            "Are you interested in comparing Farxiga to specific alternative treatments or standard care approaches currently used in elderly T2DM patients?"
                        ]
                    },
                    {
                        "role": "user",
                        "content": "I approve this research plan."
                    },
                    {
                        "role": "assistant",
                        "content": "Thank you! I'll start the research process now. You can see my progress on the right panel."
                    }
                ]
            }
        }
    ]
}
